

¹ **antigen-prime:** Simulating coupled genetic and
² antigenic evolution of influenza virus

³ Zorian T. Thornton^{*1,2}, Thien Tran^{2,3}, Marlin D. Figgins^{4,5}, John
⁴ Huddleston⁴, Trevor Bedford^{1,2,4,6}, Frederick A. Matsen IV^{1,2,6,7},
⁵ and Hugh K. Haddox^{*2}

⁶ ¹Department of Genome Sciences, University of Washington,
⁷ Seattle, WA, USA

⁸ ²Computational Biology Program, Fred Hutchinson Cancer
⁹ Research Center, Seattle, WA, USA

¹⁰ ³Paul G. Allen School of Computer Science, University of
¹¹ Washington, Seattle, WA, USA

¹² ⁴Vaccine and Infectious Disease Division, Fred Hutchinson Cancer
¹³ Research Center, Seattle, WA, USA

¹⁴ ⁵Department of Applied Mathematics, University of Washington,
¹⁵ Seattle, WA, USA

¹⁶ ⁶Howard Hughes Medical Institute, Seattle, WA, USA

¹⁷ ⁷Department of Statistics, University of Washington, Seattle, WA,
¹⁸ USA

¹⁹ January 23, 2026

*Co-corresponding authors. E-mail: zorian15@uw.edu (ZTT) or hhaddox@fredhutch.org (HKH)

20

Abstract

21

Seasonal influenza virus undergoes rapid antigenic drift to escape population immunity. Computational methods can be used to organize viral genetic diversity into antigenically similar variants and estimate variant-specific growth rates. However, benchmarking these methods is challenging because it can be difficult to accurately quantify antigenicity and growth rates in nature. Simulating viral evolution using defined selective pressures can provide ground-truth data for benchmarking. But, existing simulators do not link genetic sequences to antigenic phenotypes under selection from host populations.

22

Here, we present a forward-time epidemic simulator called **antigen-prime** that links these factors. We use it to simulate viral evolution over 30 years and validate the simulation recapitulates genetic and antigenic patterns observed in natural influenza evolution.

23

We then use the simulated data to benchmark methods for assigning variants and estimating their growth rates. We evaluated a sequence-based and a phylogenetics-based method for variant assignment, finding the former was slightly more effective at separating viruses into antigenically distinct groups. We also evaluated methods for estimating variant growth rates in one-year sliding windows. Estimates were accurate in most windows, but highly inaccurate in several others. Examining high-error windows revealed several examples of a previously unreported failure mode. In all, **antigen-prime** provides a simulation framework to benchmark models of influenza evolution, and could be used to help guide future development of these models. The source code is openly available at <https://github.com/matsengrp/antigen-prime>.

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46 1 Introduction

47 Influenza virus infects about one billion and kills hundreds of thousands of
48 people globally each year (Krammer et al., 2018). Vaccination provides the pri-
49 mary method of prevention, but the virus undergoes rapid antigenic evolution,
50 necessitating annual vaccine updates (Petrova and Russell, 2018). To track the
51 virus’s evolution, laboratories worldwide sequence tens of thousands of influenza
52 genomes each year, sharing data through public databases (Hadfield et al., 2018;
53 Shu and McCauley, 2017). Public health agencies also monitor influenza spread
54 through case counts and hospitalizations.

55 It is of interest to develop computational methods to use the above sources
56 of data to help guide vaccine updates (Morris et al., 2018). One goal of such
57 methods is to partition observed viral sequences into groups (i.e. “variants”)
58 with similar antigenic phenotypes. Another goal is to estimate variant-specific
59 growth rates, helping to quantify variant fitness in the present and forecast
60 future variant abundance.

61 For seasonal influenza virus, two main computational methods exist for
62 variant assignment. One method involves building a phylogenetic tree of ob-
63 served sequences and then partitioning the tree into clades that correspond to
64 unique variants (Neher et al., 2025). This method can incorporate prior knowl-
65 edge about which mutations are most likely to impact the virus’s antigenicity.
66 Another method involves computing pairwise distances between observed
67 sequences, and then using dimensionality reduction to embed sequences in a
68 low-dimensional space. Clustering of sequences in this space can then be used
69 to identify unique variants (Nanduri et al., 2024). Both methods have proven
70 useful for interpreting real-time influenza surveillance data (Huddleston et al.,
71 2024; Nanduri et al., 2024).

72 A variety of methods exist for estimating variant-specific growth advantages
73 from viral surveillance data. Some only consider variant-specific frequencies
74 over time, such as the fitness model by Luksza and Lässig (Luksza and Lässig,
75 2014) or multinomial logistic regression approaches (Ito et al., 2021; Obermeyer
76 et al., 2022; Piantham et al., 2021). Others also consider observed numbers of
77 case counts over time, such as the fixed growth advantage (FGA) and growth
78 advantage random walk (GARW) models from the `evofr` framework (Figgins
79 and Bedford, 2025).

80 Although these methods are widely used, it is challenging to benchmark
81 their accuracy. That is because natural populations lack known ground-truth
82 variant assignments and growth advantages. Experiments such as neutralization
83 assays or hemagglutination inhibition assays can be used to quantify antigenic
84 phenotypes of influenza viruses in a laboratory setting. However, it can be
85 difficult for experiments to fully capture antigenic selection in nature due to the
86 high level of heterogeneity in human immune responses to influenza (Kikawa
87 et al., 2025).

88 A complementary approach is to simulate viral evolution under defined se-
89 lective pressures and then use the simulated data, and associated ground-truth
90 quantities, to benchmark the above methods. Doing so would require a simulator

91 that models three key aspects of influenza evolution: (1) genetic sequence evo-
92 lution through a biologically realistic mutation processes, (2) coupled antigenic
93 evolution where mutations in epitope regions alter a virus’s antigenic pheno-
94 type, allowing escape from host immunity, and (3) sustained viral transmission
95 in a large host population, with case counts tracked over time. While numer-
96 ous pathogen-evolution simulators exist (Bedford et al., 2012; Jariani et al.,
97 2019; Moshiri et al., 2019; Ochsner et al., 2025), none fully integrate all three
98 of these components. **SANTA-SIM** (Jariani et al., 2019) models genetic sequence
99 evolution, but not antigenic phenotypes or transmission dynamics. Conversely,
100 **antigen** (Bedford et al., 2012) models transmission dynamics and antigenic
101 evolution, but does not model genetic sequence evolution. **FAVITES** (Moshiri
102 et al., 2019) models contact network transmission without antigenic evolution,
103 while **virolution** (Ochsner et al., 2025) models within-host evolution without
104 population-level antigenic drift.

105 Here, we develop a simulator called **antigen-prime** that models all three
106 components listed above. We use it to simulate 30 years of seasonal influenza
107 evolution, verifying that the simulated data reproduce influenza-like dynamics
108 across genealogical, antigenic, and epidemiological dimensions. We then use
109 the simulated data to benchmark methods for assigning variants and predicting
110 variant growth rates. While the methods perform well overall, we identify several
111 examples where they perform poorly, exposing previously unrecognized failure
112 modes that occur even with abundant data.

113 2 Results

114 2.1 Summary of antigen-prime

115 We sought to build a simulator that integrates all three components of influenza
116 evolution listed above. We achieved this by extending the **antigen** simula-
117 tor (Bedford et al., 2012), which already models transmission dynamics and
118 antigenic evolution. We updated **antigen** to include explicit genetic sequences
119 that evolve through mutation and drive antigenic change. We call this updated
120 simulator **antigen-prime**.

121 The original **antigen** implements a deme-structured SIR model to simulate
122 viral transmission dynamics and antigenic evolution under selective pressure
123 from host immunity. Each infected host carries a single virus object that is as-
124 sociated with coordinates that represent the virus’s location in a d -dimensional
125 antigenic space. Mutations to the virus move it in this space. Individual hosts
126 maintain immune memory as a collection of antigenic coordinates from previous
127 infections. When an infected host comes in contact with a susceptible host, the
128 minimum Euclidean distance in antigenic space between the virus from the in-
129 fected host and viruses from the susceptible host’s immune memory determines
130 the infection risk, with smaller distances conferring greater protection. Selection
131 to escape immune memories in the host population drives viral antigenic evolu-
132 tion. However, viruses in **antigen** are not associated with genetic sequences as




Figure 1: Schematic of how `antigen-prime` simulates coupled genetic and antigenic evolution of viruses. **A:** Each virus is represented by both a nucleotide sequence and coordinates in a d -dimensional antigenic space. Mutation events simultaneously change the nucleotide sequence and move the virus in antigenic space. **B:** During mutation events, a nucleotide site is randomly selected and mutated according to the K80 model, while antigenic coordinates are updated based on a sampled step direction θ and step size r that depends on whether the mutation is synonymous or non-synonymous and whether it occurs in an epitope or non-epitope site.

133 they exist only as points in antigenic space.

134 In `antigen-prime`, we updated the virus object to include not only the
 135 virus's coordinates in antigenic space, but also a nucleotide sequence of a
 136 protein-coding gene (Figure 1A). Simulations initialize with a single virus with
 137 a defined sequence, and this sequence evolves as the virus replicates and spreads
 138 in the host population. The user must define a subset of amino-acid sites in
 139 the protein to be “epitope sites”, where mutations have large antigenic effects
 140 (all remaining sites are considered to be “non-epitope sites”). In this paper,
 141 we used an influenza hemagglutinin (HA) nucleotide sequence that codes for
 142 a protein of length 566 amino acids. We classified 49 of these amino-acid
 143 sites to be epitope sites, using the set of epitope sites defined in Luksza and
 144 Lässig (Luksza and Lässig, 2014).

145 The nucleotide sequence of a virus object mutates at a user-defined mutation
 146 rate. Since there is only one virus object per infected host, this object's sequence

147 is like a consensus sequence within the host, and the rate at which it mutates
148 represents the rate at which mutations reach sufficient frequency within the host
149 to transmit to new hosts upon contact events. Thus, we model this rate as a
150 function of both neutral mutation and within-host purifying selection. We model
151 the neutral mutation process using the K80 mutation model (Kimura, 1980),
152 parameterized by a transition/transversion ratio $\kappa = 5.0$ (user-configurable pa-
153 rameter set to match empirical observations in influenza (Bloom and Glassman,
154 2009; Rabada et al., 2006)). Specifically, mutation events randomly select a
155 nucleotide site and assign a new nucleotide by drawing from the K80-model
156 probability distribution. We model purifying selection by rejecting a subset of
157 mutations based on their properties. Mutations that introduce stop codons are
158 rejected. Nonsynonymous mutations are probabilistically either accepted or re-
159 jected according to a user-defined “acceptance rate”, with separate acceptance
160 rates for epitope and non-epitope sites. In this paper, we use acceptance rates
161 of 0.75 and 0.2 at epitope and non-epitope sites, respectively, consistent with
162 greater purifying selection at non-epitope sites (Luksza and Lässig, 2014).

163 The antigenic effect of a nucleotide mutation depends on if and how it
164 changes the protein sequence (Figure 1B). Synonymous mutations do not alter
165 the virus’s antigenic coordinates. Nonsynonymous mutations at epitope sites
166 cause large movements in antigenic space with step sizes drawn from a gamma
167 distribution with mean 0.6 antigenic units (analogous to the original **antigen**).
168 Nonsynonymous mutations at non-epitope sites cause very small movements
169 with step sizes drawn from a gamma distribution with mean 1×10^{-5} antigenic
170 units. The direction of movement (θ) is random for both types of mutations.
171 Thus, in **antigen-prime**, antigenic evolution is mostly driven by nonsynony-
172 mous mutations at epitope sites, while other mutations accumulate with little-
173 to-no antigenic impact.

174 In summary, the main difference between **antigen** and **antigen-prime** is
175 that virus objects in **antigen-prime** have sequences. In **antigen**, mutation
176 events directly result in changes to the virus object’s location in antigenic space.
177 In **antigen-prime**, mutation events first act on the virus’s sequence, which in
178 turn can result in changes to the virus’s location in antigenic space. Other
179 aspects of the simulator are the same, including antigenic selection on viruses
180 to escape immune memory in the host population.

181 Related to antigenic selection, we have also updated **antigen-prime** to
182 record population immunity over time. This feature enables benchmarking of
183 variant-assignment methods by providing explicit fitness values for viruses. Ev-
184 ery t days, the simulator samples n hosts and records the centroid of the most
185 recent entry in each host’s immune history, representing the average antigenic
186 profile of recent infections. These immunity centroids enable fitness calcula-
187 tion for sampled viruses by computing infection risk based on the host centroid
188 values at that time.

189 2.2 Simulating long-term influenza evolution using antigen
190 -prime

191 We used `antigen-prime` to simulate 30 years of H3N2 seasonal influenza
192 evolution. We initialized simulations with the full-length HA sequence from
193 A/Beijing/32/1992. Each simulation comprised three geographical demes:
194 the Northern hemisphere, Southern hemisphere, and tropics, each with 30
195 million hosts. We ran 30 parallel replicate simulations to quantify variability in
196 outcomes.

197 As with the original `antigen`, `antigen-prime` simulations reproduced
198 influenza-like phylogenetic structure and rates of antigenic evolution. In natural
199 H3N2 evolution, the average time between two contemporaneous sequences
200 and their most recent common ancestor is expected to be ~ 3.22 years (Scotch
201 et al., 2025), reflecting influenza's spindly phylogenetic structure. The average
202 rate of antigenic change is expected to be ~ 1.6 antigenic units per year, as quantified
203 using experimental data from hemagglutination-inhibition assays (Hirst,
204 1943; Koel et al., 2013; Smith et al., 2004). Many `antigen-prime` simulations
205 resulted in values close to these numbers ([Figure S1](#)).

206 `antigen-prime` simulations also reproduced influenza-like mutational patterns.
207 As an empirical reference, we considered a phylogenetic tree that Huddleston et al.
208 made using seasonal H3N2 influenza HA sequences collected over
209 25 years (Huddleston et al., 2020). For this tree, and for each of our simulated
210 trees, we counted the number of epitope and non-epitope mutations observed
211 along the branches of the tree, separately doing so for trunk branches and side
212 branches, and using the set of epitope sites from Luksza and Lässig (Luksza and
213 Lässig, 2014). Many of the simulated trees had counts similar to the empirical
214 tree ([Figure S2](#)). Table 1 shows counts for a single simulation that reproduced
215 realistic influenza-like dynamics in terms of mutational patterns, phylogenetic
216 structure, and antigenic movement, and which we describe below in more detail.
217 On the trunk, the simulated and empirical trees have similar mutation counts,
218 and similar ratios in counts between epitope and non-epitope mutations. On
219 side branches, the mutation counts are substantially higher for the simulated
220 tree because this tree has substantially more sequences (this high sampling den-
221 sity was useful for downstream benchmarking purposes). However, the ratio of
222 counts between epitope and non-epitope mutations, which is not sensitive to
223 sampling density, is similar between the simulated and empirical trees. Given
224 the complexity of natural influenza evolution and the simplifying assumptions in
225 our model, we expect approximate rather than precise agreement with empirical
226 values.

227 In the following sections, we use the simulation characterized in Table 1
228 to benchmark methods for analyzing influenza sequences. This simulation re-
229 produced various aspects of influenza evolution. A phylogenetic tree of viruses
230 sampled from this simulation exhibits a characteristic ladder-like structure ([Fig-](#)
231 [ure 2A](#)). Case counts across the three demes display realistic seasonal patterns,
232 with Northern and Southern demes exhibiting opposite seasonal peaks and the
233 tropics showing more constant transmission ([Figure 2B](#)). The distribution of

Mutation Characteristic	Empirical Value (25 years)	Scaled Value (30 years)	Simulation Value (30 years)
<i>Trunk Mutations</i>			
Epitope mutations	50	60	66
Non-epitope mutations	32	38	49
Ratio (epitope:non-epitope)	1.56	1.56	1.35
<i>Side Branch Mutations</i>			
Epitope mutations	485	582	1254
Non-epitope mutations	1177	1412	3294
Ratio (epitope:non-epitope)	0.41	0.41	0.38

Table 1: Comparison of mutation patterns between an empirical phylogeny and the simulated phylogeny used for downstream analysis. The table shows counts of mutations occurring in epitope and non-epitope regions along the trunk vs. side branches. Empirical values are derived from 25 years of H3N2 HA sequences from Huddleston et al. (Huddleston et al., 2020), with trunk and side branch annotations following the methodology of Bedford et al. (Bedford et al., 2015). Scaled values extrapolate empirical counts to 30 years ($\times 1.2$) for comparison with simulation values. Simulation values are from a 30 year simulation.

234 sampled viruses in antigenic space reveals distinct antigenic clusters that show
235 sustained antigenic evolution over time (Figure 2C). Epitope mutations accumu-
236 late approximately linearly over time (Figure 2D) and global variant frequency
237 dynamics show sequential variant emergence-and-replacement patterns observed
238 in the original **antigen** (Bedford et al., 2012) (Figure 2E).

239 2.3 Benchmarking variant-assignment methods

240 We sought to use the above **antigen-prime** simulation to benchmark meth-
241 ods for grouping viral genetic sequences into variants with similar antigenicity,
242 with the simulation providing ground-truth coordinates of each virus in anti-
243 genic space. We evaluated three methods. The first method uses k-means
244 clustering of viruses by their ground-truth antigenic coordinates, providing a
245 baseline for comparison. The second method uses Neher’s clade suggestion al-
246 gorithm (Neher et al., 2025) to cluster viruses based on a phylogenetic tree
247 built from their sequences. This approach defines variants by considering tree
248 topology, overall genetic divergence, and amino acid changes at epitope sites,
249 and has been applied in efforts to guide seasonal influenza vaccine composi-
250 tion (Huddleston et al., 2024). We parameterized this method using the same
251 set of 49 epitope sites that we used in the simulation. The third method uses
252 **pathogen-embed** (Nanduri et al., 2024) to compute pairwise Hamming distances
253 between viral sequences, then use those data to project sequences into a low-
254 dimensional space using t-SNE, and cluster sequences in that space using k-
255 means. We configured the antigenic and sequence-based methods to produce
256 30 variants, and the phylogenetic method to produce approximately 30 variants
257 (resulting in 31) for comparison. When visualized in antigenic space, all three




Figure 2: Genetic, antigenic, and epidemiological dynamics from a 30 year antigen-prime simulation. **A:** Phylogenetic tree of 150,000 viruses sampled from the simulation, with tips colored by antigenic variant assignment. **B:** Case counts across three geographic demes (North, Tropics, South), demonstrating realistic seasonal epidemic patterns with hemispheric differences. **C:** Antigenic space of sampled viruses colored by variant, with variants assigned using k-means clustering on antigenic coordinates. The data show distinct antigenic clusters. **D:** Epitope mutations accumulate approximately linearly over time (red dashed line shows 1 mutation/year reference), indicating consistent antigenic drift throughout the simulation. **E:** Global variant frequency dynamics aggregated across all demes, showing sequential variant emergence and replacement patterns.

258 methods create largely distinct clusters ([Figure 3A-C](#)), even though the latter
259 two approaches use only genetic data. As expected, the first approach results
260 in strictly non-overlapping clusters. The latter two approaches result in clusters
261 that are mostly separated, but have some overlap, reflecting the inherent
262 difficulty in cleanly resolving antigenic boundaries from genetic data alone.

263 We quantified method performance using the following three metrics. First,
264 we quantified the number of circulating variants per year. We tuned each
265 method to produce approximately three per year to reflect real-world influenza
266 dynamics (Huddleston et al., 2024). Each method resulted in similar traces of
267 this quantity over time ([Figure 3D](#)).

268 Second, we quantified the variance in antigenic fitness among viruses as-
269 signed to a given variant ([Figure 3E](#)). Specifically, for each year, we used the
270 annual host population immunity centroid from that year to calculate the fit-
271 ness of each sampled virus from the entire simulation, where fitness represents
272 infection risk and is a function of the distance between a virus and the immunity
273 centroid in antigenic space. For each variant, we then computed the variance in
274 these fitness values among viruses assigned to that variant, and then averaged
275 these variances across all variants. The blue line from [Figure 3E](#) shows the per-
276 formance of the first variant-assignment method, which clusters viruses by their
277 ground-truth coordinates in antigenic space, and which we use as a baseline for
278 evaluating the other two methods. The blue line is close to zero for all years,
279 indicating low variance in fitness values and thus high performance. The other
280 two methods also result in low variance (see the orange and green lines), as
281 expected from their ability to effectively cluster viruses in antigenic space ([Fig-
282 ure 3B/C](#)). However, the variance of these methods is ~3-10-fold higher than
283 the blue baseline, reflecting the observation that there is some overlap between
284 clusters. The sequence-based method shows consistently lower variance, and
285 thus higher performance, than the phylogenetic method.

286 Third, we quantified the extent that the sequence- and phylogenetics-based
287 assignments agreed with the ground-truth assignments from k-means clustering
288 in antigenic space ([Figure 3F,G](#)). We quantified agreement using the normal-
289 ized information distance (NID) (Li et al., 2004); a distance metric ranging
290 from 0 to 1 where lower values indicate more agreement between two variant
291 assignments and higher values indicate less agreement. Both the sequence-based
292 and phylogenetic-based methods resulted in assignments with high overlap with
293 ground-truth assignments, with the former method showing better overlap (NID
294 = 0.226) than the latter (NID = 0.322).

295 Overall, this benchmark indicates that both the sequence-based and
296 phylogenetic-based variant-assignment methods are effective at grouping
297 viruses into antigenically similar variants, with the former method showing
298 higher performance. The success of these approaches also helps validate that
299 **antigen-prime** successfully implements the fundamental coupling between
300 genetic sequences and antigenic phenotypes that drives influenza evolution.




Figure 3: Benchmarking variant-assignment methods. **(A-C)** Variant assignments visualized in simulated antigenic space. Each panel shows the same viral sequences plotted by their antigenic coordinates, with colors representing different variants. **(D)** Number of variants circulating over time. The red dashed line marks three variants per year, reflecting typical real-world dynamics. **(E)** Average within-variant fitness variance over time. Lower values indicate better grouping of viruses with similar fitness. **(F)** Variant-assignment agreement between the sequence-based method and ground-truth antigenic variants. Bubble sizes represent the number of sequences shared between compared variants. The overlap is high (NID = 0.226). **(G)** Same as panel F, but for the phylogenetics-based method. The overlap is intermediate (NID = 0.322).

301 **2.4 Benchmarking methods for inferring variant-specific
302 growth rates**

303 Next, we sought to use the simulated data to benchmark the ability of models to
304 infer variant-specific growth rates. Natural data on SARS-CoV-2 has been used
305 to benchmark the ability of MLR models to perform this task (Abousamra et al.,
306 2024). But, previous studies have not benchmarked the more sophisticated FGA
307 and GARW models.

308 To derive ground-truth growth rates from the simulated data, we divided the
309 30 years of data into overlapping one-year windows staggered every six months,
310 capturing influenza seasons in both Northern and Southern demes. We further
311 divided the simulated data by North, South, and Tropics demes. Then, for each
312 window from each deme, we computed variant-specific frequencies and growth
313 rates in weekly time bins, using variant assignments from k-means clustering of
314 viruses in antigenic space. We omitted some variants at some time points due
315 to insufficient case or sequence count data to accurately derive growth rates.

316 We then tested the ability of the FGA and GARW models from `evofr` to
317 recover these growth rates. We separately fit each model to each window of
318 data from each deme. As input, the models take the total number of reported
319 cases amongst the host population and the observed counts for each variant in
320 the sampled viral population. They then use a Bayesian approach to estimate
321 probability distributions of variant-specific growth rates and frequencies over
322 time. To analyze model predictions, we sampled 500 times from the inferred
323 posterior distributions for variant growth rates and report the median values and
324 95 % highest posterior density (HPD) intervals. For each analysis window, we
325 then calculated the mean absolute error (MAE) between predicted and ground-
326 truth growth rates.

327 Below, we mostly focus on results from the GARW model as it allows growth
328 advantages to vary smoothly over time, accommodating situations where the
329 fixed-advantage assumption made in the FGA model may break down: for in-
330 stance, due to shifting population immunity or cross-immunity between vari-
331 ants (Figgins and Bedford, 2025). Results for the simpler FGA model show
332 comparable performance and are available in the supplement ([Figure S3](#), [Fig-
333 ure S4](#)).

334 The performance of the GARW model varied across analysis windows. For
335 many windows, the MAE values are low near zero, indicating accurate growth-
336 rate predictions ([Figure 4](#)). [Figure 4B](#) provides a detailed view of one such
337 window, which shows good agreement between variant-specific frequencies and
338 growth rates inferred by the model (see the lines) and those directly derived
339 from the simulated data (see the circles).

340 However, for several other windows, the MAE values are substantially higher,
341 pointing to inaccurate growth-rate predictions. Examining these windows re-
342 vealed a failure mode that has not been documented in previous studies. [Fig-
343 ure 4C-E](#) provides three examples of this failure mode. In each case, there is
344 one variant that initially predominates and then begins to decline in frequency
345 as one or two low-frequency variants start increasing in frequency. The model




Figure 4: GARW model performance on variant growth-rate inference. **(A)** Distribution of $\log(\text{MAE})$ values of inferred variant-specific growth rates across geographic demes. The red dashed line indicates the screening threshold used to identify analysis windows for detailed analysis. Each data point represents a single variant from a specific training window. Variants selected for panels B-E are circled. **(B-E)** Example analysis windows. Each panel shows case counts per 100,000 hosts over time (top), variant frequencies (second), case counts by variant (third), and inferred growth rates (bottom) for a given window. Points show values derived directly from the simulated data. Not all variants are shown at all time points due to data filtering on observed count thresholds for a series of timepoints (see Methods). Solid lines show median of model inferences and shaded regions indicate 95 % HPD intervals. Average $\log(\text{MAE})$ values for each variant are reported below the growth-rate plots. **(B)** Successful inference of frequencies and growth rates (North, 2027-10-01). **(C)** Growth rates underestimated near end of the analysis window (Tropics, 2048-10-01). **(D)** Growth rates overestimated for multiple variants (Tropics, 2032-10-01). **(E)** Growth rates inaccurately inferred for both variants 27 and 28 (South, 2052-10-01).

346 accurately predicts the frequency trajectory of each variant. However, in many
347 weekly time bins, the model does not accurately predict variant-specific growth
348 rates, especially in bins near the middle or end of the window when the initial
349 predominant variant begins to substantially decline in frequency. Often,
350 the prediction error is larger than the estimated model uncertainty (observed
351 growth rates fall outside the HPD interval). Strikingly, there are multiple exam-
352 ples where the predicted and observed growth rates have opposing signs, like in
353 [Figure 4D](#) where the pink variant is predicted to have a positive growth rate in
354 several time bins where it actually has a negative growth rate, or in [Figure 4C](#)
355 where the opposite is true for the purple and red variants. In general, in time
356 bins with enough data to quantify growth rates for multiple variants, when the
357 predicted growth rate is inaccurate for one variant, it tends to be inaccurate
358 for the other variants by roughly the same amount and in roughly the same
359 direction, indicating systematic bias. This bias may stem from an underlying
360 assumption in both the GARW and FGA models that variant-specific growth
361 rates tend to change in a concerted manner.

362 In all, this benchmark indicates that the GARW and FGA models are largely
363 effective at predicting variant-specific growth rates from the simulated data.
364 However, it also revealed potential problems with these models that motivate
365 additional investigation.

366 3 Discussion

367 We have presented `antigen-prime`, a simulator that jointly models the genetic
368 and antigenic evolution of viruses under selection from host population immu-
369 nity. We showed that `antigen-prime` can be used to simulate H3N2 seasonal
370 influenza-like dynamics over long timescales. The dynamics are influenza-like
371 in terms of their phylogenetic structure, antigenic evolution, and sequence-level
372 mutation patterns, with mutations at epitope sites driving antigenic change.
373 We then used the simulated data to benchmark computational methods that
374 are currently used to interpret influenza surveillance data, and have relevance
375 for public-health decision-making.

376 Our work helps address a fundamental challenge in evaluating these com-
377 putational methods: the lack of ground-truth data in natural viral populations
378 makes it difficult to assess whether the methods accurately capture the bio-
379 logical processes they aim to model. Simulated data with known ground-truth
380 values can be used to benchmark methods. But, the field lacks simulators of
381 pathogen evolution that model both genetic and antigenic evolution under se-
382 lection from host population immunity. `antigen-prime` fills the gap, enabling
383 benchmarking of the methods we analyzed in this paper.

384 The benchmarking results update our understanding of the efficacy of these
385 methods. The benchmark on variant assignment showed that both the sequence-
386 based and phylogenetic-based methods were effective at grouping viruses with
387 similar antigenic properties even without explicit access to fitness or antigenic
388 information. Interestingly, the sequence-based approach performed better than

389 the phylogenetic one. The reason for this is not immediately evident to us,
390 and could warrant future exploration. Future work could also benchmark variant
391 assignment over shorter evolutionary time scales relevant for interpreting
392 real-time influenza evolution. We note that performance on this benchmark
393 is probably higher than expected for natural viral populations, since predicting
394 phenotype from genotype is more challenging in nature due to factors not
395 captured in **antigen-prime**, such epistasis between mutations and variable im-
396 munity in the host population.

397 The benchmark on growth-rate inference showed that the GARW and FGA
398 methods performed well in most time windows, but also revealed windows where
399 model predictions dramatically differed from ground-truth. While the GARW
400 method is conceptually more flexible, this additional flexibility did not pro-
401 vide substantial advantages over the simpler FGA method in our benchmark.
402 Investigating low-performance windows identified a previously undocumented
403 failure mode. Thus, these results helped identify limitations to these methods,
404 and could be used to help guide future method development. In the future,
405 **antigen-prime** simulated data could also be used to benchmark the ability of
406 methods to forecast influenza evolution, which is also highly relevant to devel-
407 oping effective vaccines.

408 Despite capturing many features of viral evolution under immune selection,
409 **antigen-prime** makes several simplifying assumptions that limit its biological
410 realism. The fitness of simulated viruses is determined solely by their antigenic
411 phenotype. However, other models of influenza evolution also model potential
412 fitness costs of mutations at non-epitope sites (Luksza and Lässig, 2014), where
413 mutations can disrupt HA's ability to mediate viral entry. Additionally, the
414 model maintains static epitope sites throughout the simulation, and employs a
415 simple mutation model without epistatic interactions.

416 In all, **antigen-prime** provides a powerful framework for simulating sea-
417 sonal influenza evolution, enabling researchers to benchmark and guide devel-
418 opment of methods for interpreting influenza surveillance data. In the future,
419 **antigen-prime** could be tuned to simulate evolutionary dynamics of other
420 viruses, helping to benchmark methods for a variety of pathogens related to
421 human health.

4 Methods

4.1 Data and code availability

424 The **antigen-prime** simulator source code is available at <https://github.com/>
425 [matsengrp/antigen-prime](https://github.com/matsengrp/antigen-prime). Analysis scripts, simulation outputs, and code to
426 generate all figures are available at <https://github.com/matsengrp/antigen-forecasting>.

428 4.2 Implementation of antigen-prime

429 `antigen-prime` is implemented as a Java program forked from the original
430 `antigen` simulator (Bedford et al., 2012). The software is compiled using Maven
431 and requires Java 11 or higher, with dependencies specified in the project's
432 `pom.xml` file. The complete source code is available at <https://github.com/matsengrp/antigen-prime>.

433 Two major extensions distinguish `antigen-prime` from the original simulator:
434 (1) explicit genetic sequence evolution with site-specific mutation effects on
435 antigenic movement, and (2) periodic sampling of host population immunity to
436 enable fitness calculations for downstream analysis.

437 The core simulation algorithm follows the discrete-event SIR (Susceptible-
438 Infected-Recovered) framework described in Bedford et al. (Bedford et al., 2012),
439 with key extensions to couple genetic and antigenic evolution. The simulation
440 proceeds through discrete time steps, modeling viral transmission dynamics
441 across structured host populations (demes) while tracking both genetic se-
442 quences and antigenic coordinates for each virus. At each time step, the algo-
443 rithm processes infection events based on host susceptibility and viral fitness,
444 applies stochastic mutations to viral genomes according to the K80 model, up-
445 dates antigenic coordinates based on mutation type and location, and samples
446 host immunity profiles periodically to calculate population-level immunity cen-
447 troids.

448 In this paper, we use an overall viral mutation rate of $\mu = 10^{-3}$ mutations
449 per virus per day. Epitope sites comprise ~9% of the sequence (49/566 sites)
450 and have an acceptance rate of 0.75, resulting in an effective mutation rate
451 of $\mu \times 0.065$ mutations per virus per day at epitope sites. Non-epitope sites
452 comprise the remaining ~91% of the sequence and have a lower acceptance rate
453 of 0.2, reflecting greater purifying selection at these sites (Luksza and Lässig,
454 2014), resulting in an effective rate of $\mu \times 0.183$ mutations per virus per day.
455 We tuned these acceptance rates to reproduce mutational patterns observed in
456 seasonal influenza in nature (Figure S2).

458 4.3 Simulation parameterization and host population im- 459 munity sampling

460 We simulated 40 years of influenza evolution across three demes, and discarded
461 the first 10 years as burn-in. We parameterized mutation step-size distributions
462 to reflect the differential antigenic impact of epitope versus non-epitope muta-
463 tions. Non-epitope sites used $r_{ne} \sim \text{Gamma}(\alpha = 1, \beta = 0.0001)$ while epitope
464 sites used $r_e \sim \text{Gamma}(\alpha = 2.25, \beta = 0.267)$. All mutations received a step
465 direction $\theta \sim \text{Uniform}(0, 2\pi)$.

466 We sampled 150,000 viruses over the course of the simulation, proportionally
467 by prevalence across demes and time, yielding approximately 4,400 unique nu-
468 cleotide sequences to provide adequate count data for downstream growth-rate
469 inference. To track population-immunity dynamics, we calculated and saved the
470 antigenic centroid from the most recent infection stored in the immune memories

471 of 10,000 hosts from each deme every 365 days. The host population immunity
472 centroid at time t is calculated as:

$$H_t = \frac{1}{|H|} \sum_{h \in H} (\text{ag}_1^*, \text{ag}_2^*)_h \quad (1)$$

473 where H is the set of all sampled hosts across demes, $|H|$ is the total num-
474 ber of hosts sampled, and $(\text{ag}_1^*, \text{ag}_2^*)_h$ represents the two-dimensional antigenic
475 coordinates of the most recent infection for host h . This centroid represents
476 the average antigenic position of the host population’s immunity at time t and
477 is used to calculate virus fitness values in the downstream variant assignment
478 benchmark.

479 4.4 Simulation selection for benchmarking applications

480 We applied three criteria for selecting simulations suitable for benchmarking: (1)
481 realistic epidemiological dynamics with seasonal epidemic patterns in the tem-
482 perate demes and year-round transmission in the tropics, (2) summary statistics
483 matching empirical A/H3N2 HA genetic and antigenic evolution, and (3) suffi-
484 cient viral diversity for robust benchmarking of methods for variant assignment
485 and growth-rate inference.

486 To achieve the first criterion, we maintained the same antigenic and epi-
487 demiological parameter values from the original `antigen` paper by Bedford *et*
488 *al.* (Bedford et al., 2012). We also set the overall mutation rate to $\mu = 10^{-3}$
489 mutation events per individual per day. For the second criterion, we ran 120
490 total simulations with four different parameter configurations for epitope and
491 non-epitope mutation acceptance rates (epitope: 0.75 or 1.0; non-epitope: 0.1
492 or 0.2), using 30 replicates for each configuration. All 120 simulations ran to
493 completion without viral population extinction ([Figure S1](#), [Figure S2](#)).

494 We define the mean pairwise genealogical diversity π_G as the average total
495 branch length between randomly sampled virus pairs:

$$\pi_G = \frac{1}{n} \sum_{i=1}^n \left[(t_{v_A^i} - t_{\text{MRCA}^i}) + (t_{v_B^i} - t_{\text{MRCA}^i}) \right] \quad (2)$$

496 where n is the number of sampled pairs, t_v is the birth time of virus v , and
497 t_{MRCA} is the birth time of the most recent common ancestor for each pair. We
498 then applied a filtering criterion to focus on “flu-like” simulations: $\pi_G \leq 9.0$
499 years. This filtering reduced the dataset from 120 to 83 qualifying simulations.
500 For downstream variant assignment and growth rate inference benchmarking,
501 we selected a single simulation with epitope acceptance rate of 0.75 and non-
502 epitope acceptance rate of 0.2. This simulation had a simulated π_G of 3.6 years
503 and TMRCA of 3.4 years, and average antigenic movement of 1.6 units per year,
504 closely matching empirical observations. The mutation summary statistics re-
505 ported in Table 1 represent this selected simulation. Final selection involved
506 confirming that phylogenetic trees and antigenic space distributions exhibited

507 realistic influenza-like dynamics by visual inspection. Phylogenetic trees were
508 inspected to ensure they displayed ladder-like structures, and case count dynam-
509 ics were examined to confirm seasonal epidemic patterns in temperate demes
510 and year-round transmission in the tropics.

511 4.5 Variant assignment for antigen-prime simulations

512 Three variant-assignment methods were applied to the 5,900 unique sequences:
513 antigenic clustering (ground truth), sequence-based clustering, and phyloge-
514 netic variant assignment. Antigenic variants were defined by k-means clustering
515 ($k = 30$) on two-dimensional antigenic coordinates. Sequence-based variants
516 were assigned using `pathogen-embed` (Nanduri et al., 2024): (1) sequence align-
517 ment with MAFFT via `augur align`, (2) pairwise Hamming distance calculation,
518 (3) t-SNE embedding in 2D space, and (4) k-means clustering ($k = 30$) on em-
519 beddings. The $k = 30$ parameter for both methods reflects empirical influenza
520 dynamics of approximately three variants per year over the 30 year simulation.

521 Phylogenetic variants were assigned using the Neher clade assignment
522 algorithm (Neher et al., 2025) following phylogeny reconstruction and ances-
523 tral inference. The algorithm was configured to use the same epitope sites
524 defined by Luksza and Lässig (Luksza and Lässig, 2014) that are used in
525 the `antigen-prime` simulation. Phylogeny inference used IQ-TREE via `augur`
526 tree with `augur refine` refinement. Ancestral reconstruction applied `augur`
527 `ancestral` and `augur translate` with default parameters. Clade assignment
528 used parameters: bushiness branch scale 1.0, divergence scale 2.0, branch length
529 scale 2.0, minimum clade size 22 sequences, targeting approximately 30 variants
530 (resulting in 31). All variant assignments were re-labeled chronologically by
531 average birth date of constituent viruses.

532 Within-variant fitness variance was calculated to evaluate how well each
533 method grouped viruses with similar fitness. We computed fitness for all viruses
534 annually using the host population immunity centroid (Figure 1), then calcu-
535 lated average within-variant fitness variance for each assignment method.

$$\text{WSS}(t) = \frac{1}{|V|} \sum_{v \in V} \text{Var}(\omega_{t,v}) \quad (3)$$

536 where V is the set of all variants assigned by a method, $|V|$ is the total number
537 of variants, and $\omega_{t,v}$ represents the fitness values of all viruses in variant v at
538 time t .

539 Agreement between variant assignments was quantified using the normalized
540 information distance (NID) (Li et al., 2004):

$$\text{NID}(X, Y) = 1 - \frac{I(X, Y)}{H(X, Y)} \quad (4)$$

541 where $I(X, Y)$ is the mutual information between assignments X and Y , and
542 $H(X, Y)$ is their joint entropy. NID ranges from 0 (identical assignments) to 1
543 (completely independent assignments).

544 **4.6 Inferring variant growth rates with `evofr` forecasting
545 models**

546 We implemented two forecasting models from the `evofr` (Figgins and Bedford,
547 2025) framework to infer variant growth rates from simulated surveillance data.
548 The Fixed Growth Advantage (FGA) model implements a renewal equation
549 approach where each variant has a fixed multiplicative growth factor, while
550 the Growth Advantage Random Walk (GARW) model allows variant growth
551 advantages to vary smoothly over time using a random walk prior.

552 Data preparation involved extracting weekly variant-specific sequence counts
553 and case counts from simulation outputs for each analysis timepoint. Data were
554 separated by deme with analysis dates representing both in-season and out-of-
555 season periods across different epidemic contexts. The retrospective observation
556 window was limited to 365 days from each analysis date.

557 Model fitting used the `evofr` software package for both FGA and GARW
558 models. Model-specific hyperparameters were initialized with spline basis
559 functions of order 4 with 10 knots to model time-varying parameters. Gen-
560 eration time and reporting delay distributions were defined for the renewal
561 equation models, with generation times parameterized as gamma distribu-
562 tions: $g(\tau) \sim \text{Gamma}(\text{mean} = 3.0, \text{std} = 1.2)$. Sequence count data used
563 Dirichlet-Multinomial likelihood with concentration parameter 100, while case
564 count data used Negative Binomial likelihood with dispersion parameter 0.05.
565 Variational inference approximated posterior distributions of model parameters
566 using full-rank variational inference with 50,000 iterations and learning rate of
567 0.01, generating 500 posterior samples per model. We focused on the inferred
568 variant growth rates in this work.

569 **4.7 Benchmarking growth rate inference performance**

570 Empirical growth rates ($r_{\text{data},v}$) were calculated from simulated surveillance
571 data using spline-based smoothing to reduce noise. For each variant v and
572 location d , sequence data processing used univariate spline interpolation by
573 log-transforming sequence counts to handle data skew and stabilize variance,
574 applying a cubic univariate spline (degree $k = 3$) with smoothing factor $s = 1.0$
575 to the log-transformed data, then transforming the smoothed values back to the
576 original scale.

577 After obtaining smoothed sequence counts, we calculated variant-specific
578 incidence by multiplying total case counts by variant frequencies, then computed
579 empirical growth rates as the change in log-transformed variant incidence over
580 time:

$$r_{\text{data},v}(t_i) = \frac{\ln(C_d(t_i) \cdot f_{v,d}(t_i)) - \ln(C_d(t_{i-1}) \cdot f_{v,d}(t_{i-1}))}{\Delta t} \quad (5)$$

581 where $C_d(t_i)$ represents the total case counts in location d at time t_i , $f_{v,d}(t_i)$
582 represents the smoothed frequency of variant v in location d at time t_i , and Δt is
583 the time difference between observations. This approach scales the total disease

584 burden by variant-specific frequencies, providing a representation of variant-
585 specific growth rates.

586 Data filtering ensured reliable growth-rate estimates by excluding time
587 points with smoothed sequence counts below 10 sequences (due to high sam-
588 pling variance), variant frequencies below 1% of the total population (to avoid
589 stochastic effects in rare variants), and variant incidence below 50 cases on
590 any given day (to ensure sufficient case data). We required a minimum of 3
591 consecutive valid time points for a variant to be included in the growth-rate
592 benchmarking analysis.

593 Performance on growth-rate inference was evaluated using mean absolute er-
594 ror (MAE) between the medians of the inferred growth rate posteriors ($r_{\text{model},v}$)
595 and empirical ($r_{\text{data},v}$) growth rates for each variant:

$$\text{MAE}_v = \frac{1}{n} \sum_{i=1}^n |r_{\text{data},v}(t_i) - r_{\text{model},v}(t_i)| \quad (6)$$

596 where n is the number of time points for variant v . We report $\log(\text{MAE})$ for
597 each variant to facilitate comparison across the small error ranges typically
598 observed. The identification of analysis windows with unforeseen pathologies
599 was done by tediously looking at many analysis windows with exceptionally
600 high errors. Complete results, including detailed performance metrics for all
601 analysis windows, are available at <https://github.com/matsengrp/antigen-forecasting/notebooks/>.

603 5 Funding

604 This work was supported by HHMI Covid Collaboration award to FAM and TB.
605 This work was supported by NIH R01 AI165821 to TB. ZT was supported by
606 NIH R01 AI146028 and NIH T32 GM081062. FAM and TB are Howard Hughes
607 Medical Institute Investigators.

608 References

- 609 E. Abousamra, M. Figgins, and T. Bedford. Fitness models provide accurate
610 short-term forecasts of SARS-CoV-2 variant frequency. *PLOS Computational
611 Biology*, 20(9):1–20, 09 2024. doi: 10.1371/journal.pcbi.1012443. URL <https://doi.org/10.1371/journal.pcbi.1012443>.
- 613 T. Bedford, A. Rambaut, and M. Pascual. Canalization of the evolutionary
614 trajectory of the human influenza virus. *BMC Biol.*, 10:38, Apr. 2012.
- 615 T. Bedford, S. Riley, I. G. Barr, S. Broor, M. Chadha, N. J. Cox, R. S. Daniels,
616 C. P. Gunasekaran, A. C. Hurt, A. Kelso, A. Klimov, N. S. Lewis, X. Li,
617 J. W. McCauley, T. Odagiri, V. Potdar, A. Rambaut, Y. Shu, E. Skepner,
618 D. J. Smith, M. A. Suchard, M. Tashiro, D. Wang, X. Xu, P. Lemey, and

- 619 C. A. Russell. Global circulation patterns of seasonal influenza viruses vary
620 with antigenic drift. *Nature*, 523(7559):217–220, July 2015.
- 621 J. D. Bloom and M. J. Glassman. Inferring stabilizing mutations from protein
622 phylogenies: application to influenza hemagglutinin. *PLoS Comput. Biol.*, 5
623 (4):e1000349, Apr. 2009.
- 624 M. D. Figgins and T. Bedford. Inferring variant-specific effective reproduction
625 numbers from combined case and sequencing data. Sept. 2025. doi: 10.7554/
626 <http://dx.doi.org/10.7554/eLife.104802.1>.
- 627 J. Hadfield, C. Megill, S. M. Bell, J. Huddleston, B. Potter, C. Callender,
628 P. Sagulenko, T. Bedford, and R. A. Neher. Nextstrain: real-time tracking of
629 pathogen evolution. *Bioinformatics*, 34(23):4121–4123, Dec. 2018.
- 630 G. K. Hirst. Studies of antigenic differences among strains of influenza a by
631 means of red cell agglutination. *J. Exp. Med.*, 78(5):407–423, Nov. 1943.
- 632 J. Huddleston, J. R. Barnes, T. Rowe, X. Xu, R. Kondor, D. E. Wentworth,
633 L. Whittaker, B. Ermetal, R. S. Daniels, J. W. McCauley, S. Fujisaki,
634 K. Nakamura, N. Kishida, S. Watanabe, H. Hasegawa, I. Barr, K. Subbarao,
635 P. Barrat-Charlaix, R. A. Neher, and T. Bedford. Integrating genotypes and
636 phenotypes improves long-term forecasts of seasonal influenza A/H3N2 evo-
637 lution. *eLife*, 9, Sept. 2020.
- 638 J. Huddleston, T. Bedford, J. Chang, J. Lee, and R. A. Neher. Seasonal influenza
639 circulation patterns and projections for february 2024 to february 2025. 2024.
- 640 K. Ito, C. Piantham, and H. Nishiura. Predicted dominance of variant Delta of
641 SARS-CoV-2 before Tokyo Olympic Games, Japan, July 2021. *Euro Surveill.*,
642 26(27), July 2021.
- 643 A. Jariani, C. Warth, K. Deforche, P. Libin, A. J. Drummond, A. Rambaut,
644 F. A. Matsen, Iv, and K. Theys. SANTA-SIM: simulating viral sequence
645 evolution dynamics under selection and recombination. *Virus Evol.*, 5(1):
646 vez003, Jan. 2019.
- 647 C. Kikawa, A. N. Loes, J. Huddleston, M. D. Figgins, P. Steinberg, T. Grif-
648 fiths, E. M. Drapeau, H. Peck, I. G. Barr, J. A. Englund, S. E. Hensley,
649 T. Bedford, and J. D. Bloom. High-throughput neutralization measurements
650 correlate strongly with evolutionary success of human influenza strains. *eLife*,
651 Nov. 2025. doi: 10.7554/elife.106811.2. URL <http://dx.doi.org/10.7554/eLife.106811.2>.
- 653 M. Kimura. A simple method for estimating evolutionary rates of base substi-
654 tutions through comparative studies of nucleotide sequences. *J. Mol. Evol.*,
655 16(2):111–120, Dec. 1980.

- 656 B. F. Koel, D. F. Burke, T. M. Bestebroer, S. van der Vliet, G. C. M. Zondag,
657 G. Vervaet, E. Skepner, N. S. Lewis, M. I. J. Spronken, C. A. Russell, M. Y.
658 Eropkin, A. C. Hurt, I. G. Barr, J. C. de Jong, G. F. Rimmelzwaan, A. D.
659 M. E. Osterhaus, R. A. M. Fouchier, and D. J. Smith. Substitutions near the
660 receptor binding site determine major antigenic change during influenza virus
661 evolution. *Science*, 342(6161):976–979, Nov. 2013.
- 662 F. Krammer, G. J. D. Smith, R. A. M. Fouchier, M. Peiris, K. Kedzierska, P. C.
663 Doherty, P. Palese, M. L. Shaw, J. Treanor, R. G. Webster, and A. García-
664 Sastre. Influenza. *Nat. Rev. Dis. Primers*, 4(1):3, June 2018.
- 665 M. Li, X. Chen, X. Li, B. Ma, and P. M. B. Vitanyi. The similarity metric.
666 *IEEE Trans. Inf. Theory*, 50(12):3250–3264, Dec. 2004.
- 667 M. Luksza and M. Lässig. A predictive fitness model for influenza. *Nature*, 507
668 (7490):57–61, Mar. 2014.
- 669 D. H. Morris, K. M. Gostic, S. Pompei, T. Bedford, M. Luksza, R. A. Neher,
670 B. T. Grenfell, M. Lässig, and J. W. McCauley. Predictive modeling of in-
671 fluenza shows the promise of applied evolutionary biology. *Trends Microbiol.*,
672 26(2):102–118, Feb. 2018.
- 673 N. Moshiri, M. Ragonnet-Cronin, J. O. Wertheim, and S. Mirarab. FAVITES:
674 simultaneous simulation of transmission networks, phylogenetic trees and se-
675 quences. *Bioinformatics*, 35(11):1852–1861, June 2019.
- 676 S. Nanduri, A. Black, T. Bedford, and J. Huddleston. Dimensionality reduction
677 distills complex evolutionary relationships in seasonal influenza and SARS-
678 CoV-2. *Virus Evolution*, 10(1):veae087, 11 2024. ISSN 2057-1577. doi: 10.
679 1093/ve/veae087. URL <https://doi.org/10.1093/ve/veae087>.
- 680 R. A. Neher, J. Huddleston, T. Bedford, N. S. Lewis, R. Harvey, M. Galiano,
681 A. M. P. Byrne, S. James, D. Smith, M. Luksza, D. Ruchnewitz, M. Laes-
682 sig, S. Fujisaki, S. Watanabe, H. Hasegawa, N. Hassell, D. E. Wentworth,
683 R. Kondor, Y. M. Deng, C. Dapat, K. Subbarao, and I. Barr. Nomenclature
684 for tracking of genetic variation of seasonal influenza viruses. *medRxiv*, page
685 2025.12.06.25341755, Dec. 2025.
- 686 F. Obermeyer, M. Jankowiak, N. Barkas, S. F. Schaffner, J. D. Pyle,
687 L. Yurkovetskiy, M. Bosso, D. J. Park, M. Babadi, B. L. MacInnis, J. Luban,
688 P. C. Sabeti, and J. E. Lemieux. Analysis of 6.4 million SARS-CoV-2 genomes
689 identifies mutations associated with fitness. *Science*, 376(6599):1327–1332,
690 June 2022.
- 691 N. Ochsner, J. Bouman, T. G. Vaughan, T. Stadler, S. Bonhoeffer, and
692 R. R. Regoes. Viral simulation reveals overestimation bias in within-
693 host phylodynamic migration rate estimates under selection. *bioRxiv*, page
694 2025.01.06.631458, Jan. 2025.

- 695 V. N. Petrova and C. A. Russell. The evolution of seasonal influenza viruses.
696 *Nat. Rev. Microbiol.*, 16(1):47–60, Jan. 2018.
- 697 C. Piantham, N. M. Linton, H. Nishiura, and K. Ito. Estimating the elevated
698 transmissibility of the B.1.1.7 strain over previously circulating strains in Eng-
699 land using GISAID sequence frequencies. *bioRxiv*, page 2021.03.17.21253775,
700 Mar. 2021.
- 701 R. Rabidan, A. J. Levine, and H. Robins. Comparison of avian and human
702 influenza a viruses reveals a mutational bias on the viral genomes. *J. Virol.*,
703 80(23):11887–11891, Dec. 2006.
- 704 M. Scotch, T. O. C. Faleye, J. M. Wright, S. Finnerty, R. U. Halden, and
705 A. Varsani. Campus-based genomic surveillance uncovers early emergence of
706 a future dominant a(H3N2) influenza clade. *iScience*, 28(12):113941, Dec.
707 2025.
- 708 Y. Shu and J. McCauley. GISAID: Global initiative on sharing all influenza
709 data - from vision to reality. *Euro Surveill.*, 22(13):30494, Mar. 2017.
- 710 D. J. Smith, A. S. Lapedes, J. C. de Jong, T. M. Bestebroer, G. F. Rim-
711 melzwaan, A. D. M. E. Osterhaus, and R. A. M. Fouchier. Mapping the
712 antigenic and genetic evolution of influenza virus. *Science*, 305(5682):371–
713 376, July 2004.

⁷¹⁴ **Supplementary Materials**




Figure S1: Genealogical and antigenic summary statistics for 120 simulations of 30 years of H3N2-like evolution. Each point represents a single simulation. Red dashed horizontal lines represent empirical values reported in previous studies. The 9.0 diversity cutoff was used in Bedford et al. (Bedford et al., 2012), and the antigenic movement per year metric was chosen to reflect results observed in Smith et al. (Smith et al., 2004) and Koel et al. (Koel et al., 2013). **A:** Genealogical diversity (π_G). **B:** Time to most recent common ancestor (TMRCA), red dashed line used as a target value based on data from nature (Scotch et al., 2025). **C:** Antigenic movement per year, red dashed line used as a target value based on data from nature.




Figure S2: Summary of **antigen-prime** mutation statistics for 120 simulations of 30 years across various epitope/non-epitope acceptance rate configurations. Each point represents results from a single simulation. Red dashed horizontal lines represent empirical values reported in Table 1. **A:** Total number of epitope mutations observed on the trunk of the phylogeny. **B:** Total number of non-epitope mutations observed on the trunk of the phylogeny. **C:** Ratio of epitope to non-epitope mutations observed on the trunk of the phylogeny. **D:** Total number of epitope mutations observed on side branches of the phylogeny. **E:** Total number of non-epitope mutations observed on side branches of the phylogeny. **F:** Ratio of epitope to non-epitope mutations observed on side branches of the phylogeny.




Figure S3: Distribution of variant-specific growth rate inference errors comparing FGA and GARW models across geographic demes. Log-mean absolute error (log MAE) distributions show the performance of both model types in inferring exponential growth rates (r_{model}) compared to empirical growth rates (r_{data}) calculated from variant frequency dynamics. The red dashed line indicates the screening threshold used to identify analysis windows for detailed analysis. Each data point represents a single variant within a training window, with boxplots showing the distribution of errors and individual points overlaid. Both FGA and GARW models demonstrate comparable performance with similar median errors and error variance across all geographic demes.




Figure S4: FGA model performance for variant growth-rate inference. **(A)** Distribution of log MAE values of inferred variant-specific growth rates across geographic demes. The red dashed line indicates the screening threshold used to identify analysis windows for detailed analysis. Each data point represents a single variant from a specific training window. Variants selected for panels B-E are circled. **(B-E)** Examples of FGA model performance across different training windows. Average log MAE values for each variant are reported below the growth-rate plots. **(B)** Successful inference of frequencies and growth rates (North, 2027-10-01). **(C)** Growth rates underestimated near end of the analysis window (Tropics, 2048-10-01). **(D)** Growth rates overestimated for multiple variants (Tropics, 2032-10-01). **(E)** Growth rates inaccurately inferred for both variants 27 and 28 (South, 2052-10-01).